| Literature DB >> 34953396 |
Nafiseh Erfanian1, Afshin Derakhshani2, Saeed Nasseri3, Mohammad Fereidouni3, Behzad Baradaran4, Neda Jalili Tabrizi5, Oronzo Brunetti6, Renato Bernardini7, Nicola Silvestris8, Hossein Safarpour9.
Abstract
Immunotherapy has revolutionized cancer treatment and brought new aspects into tumor immunology. Effective immunotherapy will require using the suitable target antigens, optimizing the interaction between the antigenic peptide, the APC, and the T cell, and the simultaneous inhibitor of the negative regulatory process that inhibits immunotherapeutic effects and develop resistance. Tumor heterogeneity and its microenvironment is the leading cause of resistance in patients. Recently by emerging the single-cell RNA sequencing technology and its combination with immunotherapy, now we can specifically evaluate the mechanism of tumors in the face of immunotherapy agents at the single-cell resolution by detecting the transcriptional activity of immune checkpoints, screening neoantigens with high transcription levels, identifying rare cells, and other important processes. This review focuses on scRNA-seq, particularly on its application in cancer immunotherapy.Entities:
Keywords: Cancer; Immune checkpoints; Immunotherapy; ScRNA-seq
Mesh:
Substances:
Year: 2021 PMID: 34953396 DOI: 10.1016/j.biopha.2021.112558
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529